The cumulative delivery of Tucki P7+ has exceeded 10,000 units. On December 11th, Xpeng Motors announced that the cumulative delivery of Tucki P7+ has exceeded 10,000 units. He Xiaopeng, CEO of Xpeng Motors, appeared at the Guangzhou Delivery Center to deliver the 10,000th P7+ car owner, and He Xiaopeng revealed at the scene that Tucki P7+ had completed the third capacity increase.Trader: The Indian central bank is suspected of selling dollars to limit the depreciation of Indian Rupee.Yongtai Bio-product, a new open-source shareholding company, was recognized by CDE for breakthrough therapy. On December 11th, official website, China National Medical Products Administration Drug Evaluation Center (CDE), recently announced that the anti-CD19 single-chain antibody chimeric antigen receptor T cell injection (CAR-T-19 cell injection for short) developed by Yongtai Bio-B (06978.HK) was successfully included in the list of breakthrough therapy varieties by CDE, and the indication was recurrence under 25 years old/.
Academician Qiao Jie, Executive Vice President of Peking University, and his party visited Sunflower Pharmaceutical Group. On December 9th, Academician Qiao Jie, Executive Vice President of Peking University, and his party visited the headquarters of Sunflower Pharmaceutical Group for investigation and exchange. At the symposium, Tan Lei, general manager of the strategic management department of Sunflower Pharmaceutical Group, gave a detailed report on the promotion plan of the project "Peking University Medical-Sunflower Pharmaceutical Group Joint Laboratory of Bacterial Enzyme and Innovative Drugs". Sunflower Pharmaceutical Group will join hands with Peking University Medical Center, and the teams of the two sides will cooperate in depth to jointly develop new drugs based on the active substances of traditional Chinese medicine and the discovered important disease targets, promote the transformation of scientific research achievements, deepen the advantageous fields of biotechnology, and help improve the scientific research and innovation ability and technology development level. During the talks, the two sides also conducted in-depth exchanges and discussions on a number of contents.Date of hearing the liquidation petition of R&F Property's subsidiary. On Wednesday, the Hong Kong court postponed the date of hearing the liquidation petition to December 16th, when representatives of R&F Properties (Hong Kong) will go to court with lawyers of Seatown Holdings Private Equity Fund. Seatown Holdings is supported by Singapore Temasek Holdings.Yushi Technology: There is no factual basis for the company to be included in the "entity list". At present, the production and operation are normal. Yushi Technology issued a statement today: On December 10, 2024 (Beijing time), the Bureau of Industry and Security of the US Department of Commerce issued relevant announcements to include companies such as Yushi Technology in the entity list. There is no factual basis for this decision, and the company has never received any investigation and evidence collection work from any official US agency. We call on the US government to re-examine. Yushi Technology is an independent private enterprise. As a global provider of AloT products, solutions and full-stack capabilities, Yushi Technology has always adhered to the internationally accepted business ethics and compliance management concept since its establishment 13 years ago, abided by the duties of commercial companies and strictly abided by the laws and regulations of the countries where it operates. At present, the company's production and operation are normal, and this incident has no significant adverse impact on the company's operation. We have the ability to ensure continuous and stable product supply and high-quality technical support for global customers.
Hanwei Technology and others set up a new company in Hubei, including geographic remote sensing information service business. The enterprise search APP shows that recently, Hubei Hanwei Water Technology Co., Ltd. was established, with Zhao Shuai as the legal representative and a registered capital of 10 million yuan. Its business scope includes: intelligent instrument manufacturing; Industrial automatic control system device manufacturing; Research and development of mechanical equipment; Intelligent control system integration; Internet of things equipment sales; Geographic remote sensing information service, etc. Enterprise survey shows that the company is jointly owned by Hanwei Water Technology (Henan) Co., Ltd. and Li Yuhua, a subsidiary of Hanwei Technology.Academician Qiao Jie, Executive Vice President of Peking University, and his party visited Sunflower Pharmaceutical Group. On December 9th, Academician Qiao Jie, Executive Vice President of Peking University, and his party visited the headquarters of Sunflower Pharmaceutical Group for investigation and exchange. At the symposium, Tan Lei, general manager of the strategic management department of Sunflower Pharmaceutical Group, gave a detailed report on the promotion plan of the project "Peking University Medical-Sunflower Pharmaceutical Group Joint Laboratory of Bacterial Enzyme and Innovative Drugs". Sunflower Pharmaceutical Group will join hands with Peking University Medical Center, and the teams of the two sides will cooperate in depth to jointly develop new drugs based on the active substances of traditional Chinese medicine and the discovered important disease targets, promote the transformation of scientific research achievements, deepen the advantageous fields of biotechnology, and help improve the scientific research and innovation ability and technology development level. During the talks, the two sides also conducted in-depth exchanges and discussions on a number of contents.Treasury futures closed in early trading, with the main contract of 2-year Treasury futures (TS) falling by 0.06%, 5-year Treasury futures (TF) falling by 0.13%, 10-year Treasury futures (T) falling by 0.15% and 30-year Treasury futures (TL) falling by 0.26%.
Strategy guide 12-13
Strategy guide 12-13
Strategy guide 12-13